2. Search Result
Search Result
Results for "

fasting blood glucose

" in MedChemExpress (MCE) Product Catalog:

14

Inhibitors & Agonists

1

Natural
Products

Targets Recommended:
Cat. No. Product Name Target Research Areas Chemical Structure
  • HY-128642
    FAPI-2

    		FAP Cancer
    FAPI-2 is a quinoline-based fibroblast activation protein (FAP)-targeting ligand that can be labeled as 68Ga-FAPI-2 and used as a PET tracer for cancer diagnosis. FAPI-2 has advantages such as fast tracer kinetics, no need for fasting preparation, and being unaffected by blood glucose .
    FAPI-2
  • HY-12611
    Sergliflozin etabonate

    GW-869682X

    		 SGLT Metabolic Disease
    Sergliflozin etabonate (GW-869682X) is a potent and orally active sodium glucose cotransporter (SGLT2) inhibitor. Sergliflozin etabonate shows antidiabetic and antihyperglycemic effects. Sergliflozin etabonate significantly reduces non-fasting blood glucose levels in diabetic mice. Sergliflozin etabonate has the potential for the research of diabetes .
    Sergliflozin etabonate
  • HY-128642A
    FAPI-2 TFA

    		FAP Cancer
    FAPI-2 TFA is a quinoline-based fibroblast activation protein (FAP)-targeting ligand that can be labeled as 68Ga-FAPI-2 and used as a PET tracer for cancer diagnosis. FAPI-2 TFA has advantages such as fast tracer kinetics, no need for fasting preparation, and being unaffected by blood glucose .
    FAPI-2 TFA
  • HY-131334
    AMPK activator 4

    		AMPK Metabolic Disease
    AMPK activator 4 is a potent AMPK activator without inhibition of mitochondrial complex I. AMPK activator 4 selectively activates AMPK in the muscle tissues. AMPK activator 4 dose-dependently improves glucose tolerance in normal mice, and significantly lowers fasting blood glucose level and ameliorates insulin resistance in db/db diabetic mice. Anti-hyperglycemic effect .
    AMPK activator 4
  • HY-162637
    CTL26

    		Glycosidase Metabolic Disease
    CTL26 is a potent and orally active α-glucosidase inhibitor with an IC50 value of 2.81 µM. CTL26 shows anti-diabetic efficacy .
    CTL26
  • HY-N11551
    Salvifaricin

    		Others Others Metabolic Disease
    Salvifaricin is an orally active diterpenoid compound that can be isolated from Salvia leucantha Cav. and Salvia hispanica L.. Salvifaricin significantly reduces fasting blood glucose and serum triglyceride (TG) levels, and has anti-diabetic effect .
    Salvifaricin
  • HY-118113
    BVT-116429

    		11β-HSD Others
    BVT-116429 is an 11βHSD1 inhibitor with the activity of increasing adiponectin concentration and improving glucose homeostasis in diabetic mice. BVT-116429 can increase plasma adiponectin levels in diabetic KKAy mice, reduce basal insulin levels, and reduce fasting blood glucose levels after 10 days of inhibition, similar to the effect of rosiglitazone.
    BVT-116429
  • HY-19904B
    (+)-Adomeglivant

    (+)-LY2409021

    		 Endogenous Metabolite Metabolic Disease
    (+)-Adomeglivant ((+)-LY2409021) is a potent and selective glycogenotropin receptor antagonist with glucose-lowering activity. (+)-Adomeglivant reduces fasting blood glucose levels in both healthy subjects and patients with type 2 diabetes. The use of (+)-Adomeglivant can help investigate the mechanisms of hyperglycemia in type 2 diabetes. The antagonistic effect of (+)-Adomeglivant makes it challenging to assess the metabolic consequences of postprandial hyperglycemia .
    (+)-Adomeglivant
  • HY-173130
    α-Glucosidase-IN-86

    		Glycosidase Metabolic Disease Inflammation/Immunology
    α-Glucosidase-IN-86 (Compound A4) is an orally active α-glucosidase inhibitor with an IC50 of 2.72 μM. α-Glucosidase-IN-86 has high safety in mice. α-Glucosidase-IN-86 can reduce fasting blood glucose levels, improve glucose tolerance, regulate blood lipids, and has antioxidant effects in diabetic mice. α-Glucosidase-IN-86 can be used for the research of diabetes .
    α-Glucosidase-IN-86
  • HY-123171
    ASP8497

    		Dipeptidyl Peptidase Metabolic Disease
    ASP8497 is a competitive dipeptidyl peptidase IV (DPP-IV) inhibitor that reduces blood glucose levels and increases plasma active GLP-1 and insulin levels without causing hypoglycemia in fasted normal mice. ASP8497 can be utilized for antihyperglycemic research .
    ASP8497
  • HY-163066
    α-Glucosidase-IN-44

    		Glycosidase Metabolic Disease
    α-Glucosidase-IN-44 (compound IT4) is an inhibitor of α-glucosidase with IC50 value of 2.35 μM. α-Glucosidase-IN-44 has an oral activity. α-Glucosidase-IN-44 suppresses fasting blood glucose levels in diabetic mice .
    α-Glucosidase-IN-44
  • HY-163433
    α-Glucosidase-IN-57

    		Glycosidase Metabolic Disease
    α-Glucosidase-IN-57 (Compound 10c) is a competitive and orally active α-glucosidase inhibitor with an IC50 value of 0.180 μM and a Ki of 0.15 μM. α-Glucosidase-IN-57 can reduce fasting and overall blood glucose levels in mice, and can be used for anti-diabetes research .
    α-Glucosidase-IN-57
  • HY-19904A
    (+/-)-Adomeglivant

    (+/-)-LY2409021

    		 Endogenous Metabolite Metabolic Disease
    (+/-)-Adomeglivant ((+/-)-LY2409021) is a potent and selective glucagon receptor antagonist with hypoglycemic activity. (+/-)-Adomeglivant is effective in lowering blood sugar levels in both healthy people and people with type 2 diabetes. (+/-)-Adomeglivant is well tolerated by glucagon signaling blockade in patients with type 2 diabetes and significantly reduces fasting and postprandial blood glucose with a concomitant reversible elevation of aminotransferases. Glucagon signaling inhibition by (+/-)-Adomeglivant is a promising potential inhibitory approach for patients with type 2 diabetes and warrants further evaluation of its benefits and risks in longer clinical trials .
    (+/-)-Adomeglivant
  • HY-139792
    Besigliptin tosylate

    SHR117887

    		 Endogenous Metabolite Metabolic Disease
    Besigliptin tosylate (SHR117887) is a DPP-4 inhibitor with activity to improve metabolic control and β-cell function. Besigliptin tosylate can effectively reduce serum DPP-4 activity and improve oral glucose tolerance. Besigliptin tosylate significantly reduces fasting blood glucose levels and improves lipid profiles in a diabetic mouse model. The effect of besigliptin tosylate is comparable to that of the known compound vildagliptin (HY-14291) at the same concentration. Besigliptin tosylate increases insulin staining of pancreatic islet cells in chronic administration, indicating improved β-cell function .
    Besigliptin tosylate

Inquiry Online

Your information is safe with us. * Required Fields.

Salutation

  

Country or Region *

Applicant Name *

 

Organization Name *

Department *

     

Email Address *

 

Product Name *

Cat. No.

  

Requested quantity *

Phone Number *

     

Remarks

Inquiry Online

Inquiry Information

Product Name:
Cat. No.:
Quantity:
MCE Japan Authorized Agent: